Montreal, Canada
Thryv Therapeutics Inc. is a Montreal-based biotechnology startup founded in 2019, previously known as LQT Therapeutics Inc. The company's focus is on developing precision medicine solutions for genetic and drug-induced Long QT Syndromes, atrial fibrillation, and resistant cancers. Their platform of kinase inhibitors aims to provide targeted and effective treatment options.
With the recent $5.00M Convertible Note investment in June 2023 from Investissement Québec, Thryv Therapeutics is poised to further advance its research and development efforts. The company's commitment to addressing unmet medical needs through innovative therapies makes it an intriguing prospect for venture capital firms looking to invest in the biotechnology sector.
Thryv Therapeutics' unwavering dedication, encapsulated in their slogan "We will relentlessly pursue our platform of kinase inhibitors, enabling people to live their best lives. Without Limits," aligns with the growing demand for personalized healthcare solutions. As the company continues to push the boundaries of what's possible in precision medicine, it presents an exciting opportunity for investment in the pursuit of groundbreaking medical advancements.
To learn more about Thryv Therapeutics Inc. and their pioneering work, visit their website at www.thryvtrx.com.
